CMS Bound To Current Approach To Sequester Cuts For Part B Drugs, Agency Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS says it must follow its current approach to Part B drug payment cuts, but oncology provider groups maintain the administration does have discretion to exempt at least part of the ASP plus 6% payment from the required 2% reduction under the sequester.
You may also be interested in...
Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs
A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.